NeuroSense’s novel drug, PrimeC, is a combination therapy, which aims to inhibit the progression of ALS, by mitigating the degeneration and inflammation of motor neurons. The disease-modifying drug is designed to target multiple ALS pathways, including regulation of microRNA synthesis, reduction of neuroinflammation, and modulation of iron accumulation. PrimeC has received orphan drug status from … Continue reading PrimeC